Recent and future antiepileptic drugs and their impact on cognition: what can we expect?

References

• Trimble MRE, Dodson WEE. Epilepsy and Quality of Life: International Workshop: Papers.Raven Press, New York, NY, USA (1994).
   Google Scholar
• Austin JK, Huberty TJ, Huster GA, Dunn DW. Does academic achievement in children with epilepsy change over time? Dev. Med. Child Neurol. 41(7), 473–479 (1999).
   PubMed Web of Science ®Google Scholar
• Mula M, Trimble MR. Antiepileptic drug-induced cognitive adverse effects: potential mechanisms and contributing factors. CNS Drugs 23(2), 121–137 (2009).
   PubMed Web of Science ®Google Scholar
• Loring DW, Marino S, Meador KJ. Neuropsychological and behavioral effects of antiepilepsy drugs. Neuropsychol. Rev. 17(4), 413–425 (2007).
   PubMed Web of Science ®Google Scholar
• Hermann B, Meador KJ, Gaillard WD, Cramer JA. Cognition across the lifespan: antiepileptic drugs, epilepsy, or both? Epilepsy Behav. 17(1), 1–5 (2010).
   PubMedGoogle Scholar
• Dreifuss FE. Cognitive function – victim of disease or hostage to treatment? Epilepsia 33(Suppl. 1), S7–12 (1992).
   PubMedGoogle Scholar
• Kanner AM, Wuu J, Faught E, Tatum WO 4th, Fix A, French JA; PADS Investigators. A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav. 4(5), 548–552 (2003).
   PubMed Web of Science ®Google Scholar
• Doty P, Rudd GD, Stoehr T, Thomas D. Lacosamide. Neurotherapeutics 4(1), 145–148 (2007).
   PubMed Web of Science ®Google Scholar
• Halász P, Kälviäinen R, Mazurkiewicz-Beldzinska M et al.; SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 50(3), 443–453 (2009).
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E. Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures. Drugs Today 44(1), 35–40 (2008).
   PubMed Web of Science ®Google Scholar
• Chung S, Sperling MR, Biton V et al.; SP754 Study Group. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 51(6), 958–967 (2010).
   PubMed Web of Science ®Google Scholar
• Higgins GA, Breysse N, Undzys E et al. Comparative study of five antiepileptic drugs on a translational cognitive measure in the rat: relationship to antiepileptic property. Psychopharmacology (Berl.) 207(4), 513–527 (2010).
   PubMedGoogle Scholar
• Heaney D, Walker MC. Rufinamide. Drugs Today 43(7), 455–460 (2007).
   PubMed Web of Science ®Google Scholar
• Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome. Neurology 70(21), 1950–1958 (2008).
   PubMed Web of Science ®Google Scholar
• Resnick T, Arzimanoglou A, Brown LW et al. Rufinamide from clinical trials to clinical practice in the United States and Europe. Epileptic Disord. 13(Suppl. 1), S27–S43 (2011).
   PubMedGoogle Scholar
• Aldenkamp AP, Alpherts WC. The effect of the new antiepileptic drug rufinamide on cognitive functions. Epilepsia 47(7), 1153–1159 (2006).
   PubMed Web of Science ®Google Scholar
• French JA, Abou-Khalil BW, Leroy RF et al.; RESTORE 1/Study 301 Investigators. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 76(18), 1555–1563 (2011).
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Lerche H, Gil-Nagel A et al.; RESTORE 2 Study Group. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 75(20), 1817–1824 (2010).
   PubMed Web of Science ®Google Scholar
• Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM; 205 Study Group. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 68(15), 1197–1204 (2007).
   PubMed Web of Science ®Google Scholar
• Dencker D, Husum H. Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder. Behav. Brain Res. 207(1), 78–83 (2010).
   PubMedGoogle Scholar
• Dencker D, Dias R, Pedersen ML, Husum H. Effect of the new antiepileptic drug retigabine in a rodent model of mania. Epilepsy Behav. 12(1), 49–53 (2008).
   PubMed Web of Science ®Google Scholar
• Korsgaard MP, Hartz BP, Brown WD, Ahring PK, Strøbaek D, Mirza NR. Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels. J. Pharmacol. Exp. Ther. 314(1), 282–292 (2005).
   PubMedGoogle Scholar
• Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin. Investig. Drugs 15(6), 637–647 (2006).
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 83(1), 1–43 (2009).
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Gabbai AA, Hufnagel A, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res. 89(2–3), 278–285 (2010).
   PubMed Web of Science ®Google Scholar
• Elger C, Bialer M, Cramer JA, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 48(3), 497–504 (2007).
   PubMed Web of Science ®Google Scholar
• Elger C, Halász P, Maia J, Almeida L, Soares-da-Silva P; BIA-2093-301 Investigators Study Group. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group Phase III study. Epilepsia 50(3), 454–463 (2009).
   PubMed Web of Science ®Google Scholar
• Gil-Nagel A, Lopes-Lima J, Almeida L, Maia J, Soares-da-Silva P; BIA-2093-303 Investigators Study Group. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol. Scand. 120(5), 281–287 (2009).
   PubMed Web of Science ®Google Scholar
• Halász P, Cramer JA, Hodoba D et al.; BIA-2093-301 Study Group. Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy. Epilepsia 51(10), 1963–1969 (2010).
   PubMed Web of Science ®Google Scholar
• Chang XC, Yuan H, Wang Y, Xu HQ, Zheng RY. Eslicarbazepine acetate add-on for drug-resistant partial epilepsy. Cochrane Database Syst. Rev. 12, CD008907 (2011).
   Google Scholar
• Milovan D, Almeida L, Romach MK et al. Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers. Epilepsy Behav. 18(4), 366–373 (2010).
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res. 92(2–3), 89–124 (2010).
   PubMed Web of Science ®Google Scholar
• French JA, Costantini C, Brodsky A, von Rosenstiel P; N01193 Study Group. Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology 75(6), 519–525 (2010).
   PubMed Web of Science ®Google Scholar
• Meador KJ, Gevins A, Leese PT, Otoul C, Loring DW. Neurocognitive effects of brivaracetam, levetiracetam, and lorazepam. Epilepsia 52(2), 264–272 (2011).
   PubMed Web of Science ®Google Scholar
• Krauss GL, Bar M, Biton V et al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol. Scand. 125(1), 8–15 (2012).
   PubMed Web of Science ®Google Scholar
• Karasawa J, Shimazaki T, Kawashima N, Chaki S. AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. Brain Res. 1042(1), 92–98 (2005).
   PubMed Web of Science ®Google Scholar
• Shimazaki T, Kaku A, Chaki S. Blockade of the metabotropic glutamate 2/3 receptors enhances social memory via the AMPA receptor in rats. Eur. J. Pharmacol. 575(1–3), 94–97 (2007).
   PubMedGoogle Scholar
• Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 232(4753), 1004–1007 (1986).
   PubMed Web of Science ®Google Scholar
• Hu AQ, Wang ZM, Lan DM et al. Inhibition of evoked glutamate release by neurosteroid allopregnanolone via inhibition of l-type calcium channels in rat medial prefrontal cortex. Neuropsychopharmacology 32(7), 1477–1489 (2007).
   PubMedGoogle Scholar